Real-time monitoring of acute liver-allograft rejection using the banff schema

Transplantation

Volumn 74, Issue 9, 2002, Pages 1290-1296

  Demetris, A Juan ^a   Ruppert, K ^b   Dvorchik, I ^a   Jain, A ^a   Minervini, M ^c   Nalesnik, M A ^a   Randhawa, P ^a   Wu, T ^a   Zeevi, A ^a   Abu Elmagd, K ^a   Eghtesad, B ^a   Fontes, P ^a   Cacciarelli, T ^a   Marsh, W ^a   Geller, D ^a   Fung, J J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; TACROLIMUS;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGRAFT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BANFF SCHEMA; DISEASE SEVERITY; GRAFT FAILURE; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MONITORING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0037112889     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200211150-00016     Document Type: Article

References (64)

1. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997;25(3):658.
2. Porter KA. Pathology of liver transplantation. Transplant Rev 1969;2:129.
3. Vierling JM, Fennell RH Jr. Histopathology of early and late human hepatic allograft rejection: Evidence of progressive destruction of interlobular bile ducts. Hepatology 1985;5(6):1076.
4. Williams JW, Peters TG, Vera SR, et al. Biopsy-directed immunosuppression following hepatic transplantation in man. Transplantation 1985; 39(6):589.
5. Portmann B, Wight DGD. Pathology of liver transplantation. In: Calne R, ed. Liver Transplantation. London, Grune & Stratton 1987, p 435.
6. Snover DC, Freese DK, Bloomer JR, et al. An analysis of histological prognostic features of liver allograft rejection based on 270 serial biopsies. Transplant Proc 1987;19(1 Pt 3):2457.
7. Kemnitz J, Gubernatis G, Bunzendahl H, et al. Criteria for the histopathological classification of liver allograft rejection and their clinical relevance. Transplant Proc 1989;21(1 Pt 2):2208.
8. Kemnitz J, Ringe B, Cohnert TR, et al. Bile duct injury as a part of diagnostic criteria for liver allograft rejection. Hum Pathol 1989;20(2): 132.
9. Hubscher SG, Clements D, Elias E, et al. Biopsy findings in cases of rejection of liver allograft. J Clin Pathol 1985;38(12):1366.
10. Snover DC, Freese DK, Sharp HL, et al. Liver allograft rejection. An analysis of the use of biopsy in determining outcome of rejection. Am J Surg Pathol 1987;11(1):1.
11. Demetris AJ, Qian SG, Sun H, et al. Liver allograft rejection: An overview of morphologic findings. Am J Surg Pathol 1990;14(suppl 1):49.
12. Demetris AJ, Seaberg EC, Batts KP, et al. Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995;21(2):408.
13. Hubscher S. Diagnosis and grading of liver allograft rejection: A European perspective. Transplant Proc 1996;28(1):504.
14. Datta Gupta S, Hudson M, Burroughs AK, et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 1995;21(1):46.
15. Williams JW, Foster PF, Sankary HN. Role of liver allograft biopsy in patient management. Semin Liver Dis 1992;12(1):60.
16. Starzl TE, Kaupp HA, Brock DR, et al. Studies on the rejection of the transplanted homologous dog liver. Surg Obstet Gyncol 1961;112(2):135.
17. McBride RA, Wheeler HB, Smith LL, et al. Homotransplantation of the canine liver as an orthotopic vascularized graft. Am J Pathol 1962;41(5): 501.
18. Ormonde DG, de Boer WB, Kierath A, et al. Banff schema for grading liver allograft rejection: Utility in clinical practice. Liver Transpl Surg 1999; 5(4):261.
19. Zhang JL, Yamaguchi Y, Mori K, et al. A serine protease inhibitor, N-alpha-tosyl-l-lysine chloromethyl ketone, prolongs rat hepatic allograft survival. J Surg Res 2001;96(2):296.
20. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001;7(5):442.
21. Neil DA, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 2002;35(3):639.
22. Demetris AJ, Lasky S, Van Thiel DH, et al. Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol 1985;118(1):151.
23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696.
24. Wei YL, Detre KM, Everhart JE. The NIDDK liver transplantation database. Liver Transpl Surg 1997;3(1):10.
25. Snover DC, Sibley RK, Freese DK, et al. Orthotopic liver transplantation: A pathological study of 63 serial liver biopsies from 17 patients with special reference to the diagnostic features and natural history of rejection. Hepatology 1984;4(6):1212.
26. Kemnitz J, Gubernatis G, Cohnert TR, et al. Histopathologic diagnosis of rejection in liver allografts. Hum Pathol 1989;20(10):1030.
27. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology 1998; 28(3):638.
28. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med 1994;331(17):1110.
29. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344(8920):423.
30. Fung J, Todo S, Abu-Elmagd K, et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. Transplant Proc 1993;25(1 Pt 2):1130.
31. Starzl TE, Porter KA, Putnam CW, et al. Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet 1976;142(4):487.
32. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 1999;5(4 suppl 1):S30.
33. Jain A, Demetris AJ, Kashyap R, et al. Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl 2001;7(7):623.
34. Blakolmer K, Jain A, Ruppert K, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: Long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000;69(11):2330.
35. Lunz JG 3rd, Contrucci S, Ruppert K, et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: Increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol 2001; 158(4):1379.
36. Starzl TE, Marchioro TL, Porter KA, et al. Factors determining short- and long-term survival after orthotopic liver homotransplantation in the dog. Surgery 1965;58:131.
37. Ramm GA, Carr SC, Bridle KR, et al. Morphology of liver repair following cholestatic liver injury: Resolution of ductal hyperplasia, matrix deposition and regression of myofibroblasts. Liver 2000;20(5):387.
38. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124(11):1599.
39. Demetris AJ, Seaberg EC, Batts KP, et al. Chronic liver allograft rejection: A National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Am J Surg Pathol 1998;22(1):28.
40. Blakolmer K, Seaberg EC, Batts K, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol 1999;23(11):1328.
41. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: Working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000;31(3):792.
42. Freese P, Svalander CT, Molne J, et al. Chronic allograft nephropathy: Biopsy findings and outcome. Nephrol Dial Transplant 2001;16(12):2401.
43. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001;71(4):515.
44. Lehtonen SR, Taskinen EI, Isoniemi HM. Histological alterations in implant and one-year protocol biopsy specimens of renal allografts. Transplantation 2001;72(6):1138.
45. Starzl TE, Murase N, Demetris A, et al. The mystique of hepatic tolerogenicity. Semin Liver Dis 2000;20(4):497.
46. Liu Y. Hepatocyte growth factor and the kidney. Curr Opin Nephrol Hypertens 2002;11(1):23.
47. Starzl TE. A tolerogenic strategy for organ transplantation. Transplantation (in press).
48. Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nature Reviews: Immunology 2001;1:233.
49. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N Engl J Med 1998;339(26):1905.
50. Calne R, Moffatt SD, Friend PJ, et al. Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. Nippon Geka Gakkai Zasshi 2000;101(3):301.
51. Knechtle SJ, Hamawy MM, Hu H, et al. Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunol Rev 2001;183:205.
52. Montgomery SP, Hale DA, Hirshberg B, et al. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev 2001;183:214.
53. Thomas JM, Hubbard WJ, Sooudi SK, et al. STEALTH matters: A novel paradigm of durable primate allograft tolerance. Immunol Rev 2001; 183:223.
54. Dousset B, Hubscher SG, Padbury RT, et al. Acute liver allograft rejection: Is treatment always necessary? Transplantation 1993;55(3):529.
55. Kamada N. The immunology of experimental liver transplantation in the rat. Immunology 1985;55(3):369.
56. Qian S, Demetris AJ, Murase N, et al. Murine liver allograft transplantation: Tolerance and donor cell chimerism. Hepatology 1994;19(4):916.
57. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning ofimmunosuppression in long-term liver transplant recipients. Transplantation 1995;59(2): 212.
58. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63(2):243.
59. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72(3):449.
60. Demetris AJ, Murase N, Ye Q, et al. Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 1997;150(2):563.
61. Demetris AJ, Qian S, Sun H, et al. Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol 1991;138(3):609.
62. Demetris AJ, Fung JJ, Todo S, et al. FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991;23(6):3005.
63. Tsamandas AC, Jain AB, Felekouras ES, et al. Central venulitis in the allograft liver: A clinicopathologic study. Transplantation 1997;64(2):252.
64. Krasinskas AM, Ruchelli ED, Rand EB, et al. Central venulitis in pediatric liver allografts. Hepatology 2001;33(5):1141.